NEW YORK, Jan 29 – The life sciences division of IBM is scheduled to announce a new proteomics alliance Tuesday and analysts have speculated that MDS Proteomics of Toronto is Big Blue’s latest partner, Reuters reported Monday.
IBM said in a media alert last week that it would hold a press conference in Canada on Tuesday to announce a new proteomics alliance with an undisclosed company. News of the press conference, which is scheduled to be held in Toronto, fueled speculation about the identity of IBM’s partner.
On Monday, Reuters cited two anonymous sources as saying that IBM’s partner was most likely MDS Proteomics of Toronto. An unnamed biotech analyst told Reuters that, besides a small proteomics company called Integrative Proteomics, there aren’t any other proteomics companies in Toronto.
An IBM spokeswoman would not comment on the report.
IBM has launched a handful of genomics partnerships since its announcement this summer that it would invest $100 million in the life sciences sector. In September, the company announced a deal to provide its DiscoveryLink data management software to Incyte.
IBM is scheduled to make the announcement Tuesday afternoon at 1 pm EST.